Palifosfamide

    • Catalog No.:MC1378
    • Description
    • CasNo:
    • 31645-39-3
    • MolecularFormula:
    • C4H11Cl2N2O2P
    • Purity:
    • >98%
    • Target:
    • DNA Alkylator/Crosslinker
    • IC50:
    • No data
    • In Vitro:
    • Palifosfamide lysine (ZIO-201) is a stable form of palifosfamide. Palifosfamide lysine has broad activity in sarcoma lines in vitro. The IC50 ranges from 2.25 ro 6.75 μM for most cell lines except OS222 (IC50=31.5 μM)[1].
    • In Vivo:
    • Tumor growth inhibition is seen in both OS31 and OS33 xenografts and the RMS xenograft resulting in a significant difference in event-free survival between the control and the treated groups. Differential gene expression of ALDH3A1 but not ALDH1A1 is noted in the OS31 xenograft[1]. Stabilized palifosfamide administered to mice suppresses MX-1 tumor growth by greater than 80% with 17% complete antitumor responses. Oral bioavailability in rats is 48-73% of parenteral administration, and antitumor activity in mice is equivalent by both routes. Treatment with palifosfamide-tris combined with docetaxelor doxorubicin at optimal regimens results in complete tumor regression in 62-75% of mice[2].
    • Fields:
    • Palifosfamide is a novel molecule for the treatment of sof tissue sarcoma.
    • Specificity:
    • Target: DNA Alkylator/Crosslinker. Fields: Palifosfamide is a novel molecule for the treatment of sof tissue sarcoma.
    • Concentration:
    • >98%
    • Storage Stability:
    • 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO
    • MolecularWeight(Da):
    • 221.02
    • References:
    • [1]. Hingorani P, et al. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. Cancer Chemother Pharmacol. 2009 Sep;64(4):733-
    • Products Images